Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.36 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.36 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | CES2 | O00748 | 2/20 | 0.34 |
| ▸ | CES1 | P23141 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL1322825 | 1.00 | TDP1 (0.41) | TDP1ALDH1A1LMNASRD5A2CA2 | |
| Water SCHEMBL4385611 | 1.00 | TDP1 (0.41) | TDP1ALDH1A1LMNASRD5A2CA2 | |
| SCHEMBL72683 | 0.99 | TDP1 (0.42) | TDP1ALDH1A1LMNASRD5A2CA2 | |
| SCHEMBL2986285 | 0.99 | TDP1 (0.42) | TDP1ALDH1A1LMNASRD5A2CA2 | |
| SCHEMBL27955132 | 0.99 | TDP1 (0.42) | TDP1ALDH1A1LMNASRD5A2CA2 | |
| SCHEMBL5461407 | 0.99 | TDP1 (0.42) | TDP1ALDH1A1LMNASRD5A2CA2 | |
| SCHEMBL72172 | 0.99 | TDP1 (0.42) | TDP1ALDH1A1LMNASRD5A2CA2 | |
| SCHEMBL88252 | 0.99 | TDP1 (0.42) | TDP1ALDH1A1LMNASRD5A2CA2 | |
| SCHEMBL6532888 | 0.99 | TDP1 (0.42) | TDP1ALDH1A1LMNASRD5A2CA2 | |
| SCHEMBL7348978 | 0.97 | TDP1 (0.41) | TDP1ALDH1A1LMNASRD5A2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230122169-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | CELLTRION, INC. (KR) | 2023-04-20 | — | — | US | claimed |
| EP-3858816-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | Celltrion, Inc. (KR) | 2021-08-04 | — | — | EP | claimed |
| CN-112739686-A | Novel process for the preparation of (-) -xylometazoline succinate | 赛特瑞恩股份有限公司 | 2021-04-30 | — | — | CN | claimed |
| WO-2020067683-A1 | NOVEL PROCESS FOR THE PREPARATION OF (+)-CIBENZOLINE SUCCINATE | CELLTRION INC. (KR) | 2020-04-02 | — | — | WO | claimed |
| WO-2020067684-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | (주)셀트리온 | 2020-04-02 | — | — | WO | claimed |
| US-4447622-A | SALT FORMATION WITH DI-P-TOLUOYL-D-TARTARIC ACID | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH RAFI MARG (IN) | 1984-05-08 | — | — | US | claimed |
| US-12533343-B2 | Method for preparing (−)-cibenzoline succinate | CELLTRION, INC. (KR) | 2026-01-27 | — | — | US | disclosed |
| US-20250262308-A1 | Compositions and Methods for Modulating Dopamine Receptor Activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-08-21 | — | — | US | disclosed |
| EP-4522172-A1 | COMPOSITIONS AND METHODS FOR MODULATING DOPAMINE RECEPTOR ACTIVITY | The Regents of the University of California (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-112739686-B | Novel process for the preparation of (-) -sibutrazoline succinate | 赛特瑞恩股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| WO-2024075139-A1 | A PROCESS FOR PREPARATION OF FINERENONE AND INTERMEDIATES THEREOF | MAITHRI DRUGS PRIVATE LIMITED (IN) | 2024-04-11 | — | — | WO | disclosed |
| CN-117843454-A | Menthol slow-release eutectic compound and preparation method and application thereof | 湖北中烟工业有限责任公司 | 2024-04-09 | — | — | CN | disclosed |
| WO-2023220526-A1 | COMPOSITIONS AND METHODS FOR MODULATING DOPAMINE RECEPTOR ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-0216247-A2 | Use of alpha 2 adrenergic receptor antagonists for the production of pharmaceutical compositions for treating colonic spasm, irritable bowel syndrome and constipation and process for preparing such pharmaceutical compositions | MERCK & CO. INC. (US) | 1987-04-01 | — | — | EP | disclosed |
| EP-0214556-A1 | Substituted hexahydro-arylquinolizine derivatives, processes for their preparation and pharmaceutical composition containing them | MERCK & CO. INC. (US) | 1987-03-18 | — | — | EP | disclosed |
| EP-0204254-A2 | Substituted hexahydro arylquinolizines, processes for their preparation and pharmaceutical compositions containing them | MERCK & CO. INC. (US) | 1986-12-10 | — | — | EP | disclosed |
| US-4447622-A | SALT FORMATION WITH DI-P-TOLUOYL-D-TARTARIC ACID | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH RAFI MARG (IN) | 1984-05-08 | — | — | US | disclosed |
| US-4447622-A | SALT FORMATION WITH DI-P-TOLUOYL-D-TARTARIC ACID | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH RAFI MARG (IN) | 1984-05-08 | — | — | US | disclosed |
| US-4399141-A | 5-Alkyl or hydroxyalkyl substituted-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imines and anticonvulsant use thereof | MERCK & CO., INC. (US) | 1983-08-16 | — | — | US | disclosed |
| US-4335126-A | SEDATIVES, TRANQUILIZERS, AND ANTIPYRETICS; NEUROLEPTIC AND ANTIEDEMIC AGENTS | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1982-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230122169-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | SDHA, SDHB, ALDH5A1 | ADRB2 1861/4885ADRB1 1485/4885ADRB3 2181/4885 |
| US-20250262308-A1 | Compositions and Methods for Modulating Dopamine Receptor Activity | PARK7, PRLHR, SNCA | ADRB2 277/4885ADRB1 508/4885ADRB3 319/4885 |
| US-12533343-B2 | Method for preparing (−)-cibenzoline succinate | CIP2A, CACNA1A, SDHA | ADRB2 540/4885ADRB1 650/4885ADRB3 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.